2021
Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19
Azmy V, Kaman K, Tang D, Zhao H, Dela Cruz C, Topal JE, Malinis M, Price CC. Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19. Journal Of Clinical Immunology 2021, 41: 738-747. PMID: 33459964, PMCID: PMC7812117, DOI: 10.1007/s10875-020-00949-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedBiomarkersCOVID-19COVID-19 Drug TreatmentCytokine Release SyndromeCytokinesDrug Therapy, CombinationFeasibility StudiesFemaleGlucocorticoidsHospitalizationHumansImmunologic FactorsMaleMiddle AgedRetrospective StudiesSARS-CoV-2Severity of Illness IndexTreatment OutcomeYoung AdultConceptsIL-10 levelsIL-6IL-10Disease severityCytokine profileD-dimerTreatment algorithmCritical SARS-CoV-2 infectionCOVID-19SARS-CoV-2 infectionAdministration of tocilizumabAdmission IL-6Maximum oxygen requirementsTocilizumab-treated patientsElevated IL-6Immune-modulating therapyCritical COVID-19Retrospective chart reviewTertiary care centerIL-6 levelsMean IL-6IL-6 inhibitionAdministration of glucocorticoidsRole of cytokinesCytokine elevation
2020
Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease
Zhou Z, Price CC. Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease. Expert Opinion On Investigational Drugs 2020, 29: 1407-1412. PMID: 33094669, DOI: 10.1080/13543784.2020.1840549.BooksMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedClinical Trials as TopicCOVID-19COVID-19 Drug TreatmentCytokine Release SyndromeHumansInterleukin-6PneumoniaConceptsCytokine release syndromeIL-6 inhibitorsRelease syndromeSafety profileInterleukin-6Mild safety profileRandomized clinical trialsTreatment of patientsAvailable clinical dataCOVID-19COVID-19 diseaseCOVID-19 managementNovel coronavirus pneumoniaHyperinflammatory stateClinical outcomesHealthcare burdenClinical trialsClinical dataObservational studyImmune responseLong-term effectsClinical reportsLiterature searchCoronavirus pneumoniaTocilizumabTocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomes